Genitourinary highlights
Paper picks and regulatory news, newest first.
October 2026
- Are we underestimating aggressive prostate cancer by missing its most important histological warning signs?
Cribiform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Publication pick. Nature Reviews Urology. October 15, 2026.
- Can combining targeted radioligand therapy with SBRT more than double progression-free survival in oligorecurrent prostate cancer?
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR)
Publication pick. Journal of Clinical Oncology. October 12, 2026.
- Can a blood test detect cancer earlier—but still fail to demonstrate clinical utility?
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis
Publication pick. NEJM. October 9, 2026.
- What if metastatic bladder cancer spreads not just from the primary tumour, but continuously from one metastasis to another?
Evolution and heterogeneity of lethal metastatic bladder cancer subtypes
Publication pick. Nature. October 6, 2026.
- Prostate cancer treatment is evolving faster than ever - but are our clinical pathways keeping pace?
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic
Regulatory news. European Urology. October 5, 2026.
- Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced RCC
Could biomarkers help us better identify which patients with advanced RCC are most likely to benefit from immunotherapy?
Publication pick. October 3, 2026.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.